vs

Side-by-side financial comparison of DoubleVerify Holdings, Inc. (DV) and Lantheus Holdings, Inc. (LNTH). Click either name above to swap in a different company.

Lantheus Holdings, Inc. is the larger business by last-quarter revenue ($406.8M vs $180.8M, roughly 2.2× DoubleVerify Holdings, Inc.). Lantheus Holdings, Inc. runs the higher net margin — 13.3% vs 3.5%, a 9.8% gap on every dollar of revenue. On growth, DoubleVerify Holdings, Inc. posted the faster year-over-year revenue change (9.6% vs 4.0%). Lantheus Holdings, Inc. produced more free cash flow last quarter ($81.4M vs $-6.4M). Over the past eight quarters, DoubleVerify Holdings, Inc.'s revenue compounded faster (7.7% CAGR vs 4.9%).

Double Vision is a Malaysian production studio. Established in 1985, it has production hubs in Malaysia and Indonesia. Double Vision produces over 1,400 hours of television programming per year in various languages and genres for the regional market. It also houses international entertainment TV network, Channel [V], in its studios.

Lantheus Holdings, Inc. is a global healthcare firm specializing in the development, manufacturing and commercialization of innovative diagnostic imaging agents and related solutions. Its offerings cover core medical segments including oncology, cardiology and urology, with primary markets across North America and other key global regions.

DV vs LNTH — Head-to-Head

Bigger by revenue
LNTH
LNTH
2.2× larger
LNTH
$406.8M
$180.8M
DV
Growing faster (revenue YoY)
DV
DV
+5.5% gap
DV
9.6%
4.0%
LNTH
Higher net margin
LNTH
LNTH
9.8% more per $
LNTH
13.3%
3.5%
DV
More free cash flow
LNTH
LNTH
$87.8M more FCF
LNTH
$81.4M
$-6.4M
DV
Faster 2-yr revenue CAGR
DV
DV
Annualised
DV
7.7%
4.9%
LNTH

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
DV
DV
LNTH
LNTH
Revenue
$180.8M
$406.8M
Net Profit
$6.4M
$54.1M
Gross Margin
59.2%
Operating Margin
8.6%
19.0%
Net Margin
3.5%
13.3%
Revenue YoY
9.6%
4.0%
Net Profit YoY
171.5%
558.8%
EPS (diluted)
$0.04
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DV
DV
LNTH
LNTH
Q1 26
$180.8M
Q4 25
$205.6M
$406.8M
Q3 25
$188.6M
$384.0M
Q2 25
$189.0M
$378.0M
Q1 25
$165.1M
$372.8M
Q4 24
$190.6M
$391.1M
Q3 24
$169.6M
$378.7M
Q2 24
$155.9M
$394.1M
Net Profit
DV
DV
LNTH
LNTH
Q1 26
$6.4M
Q4 25
$29.3M
$54.1M
Q3 25
$10.2M
$27.8M
Q2 25
$8.8M
$78.8M
Q1 25
$2.4M
$72.9M
Q4 24
$23.4M
$-11.8M
Q3 24
$18.2M
$131.1M
Q2 24
$7.5M
$62.1M
Gross Margin
DV
DV
LNTH
LNTH
Q1 26
Q4 25
82.5%
59.2%
Q3 25
82.3%
57.9%
Q2 25
82.5%
63.8%
Q1 25
81.2%
63.8%
Q4 24
82.0%
63.5%
Q3 24
82.6%
63.9%
Q2 24
83.3%
64.9%
Operating Margin
DV
DV
LNTH
LNTH
Q1 26
8.6%
Q4 25
18.4%
19.0%
Q3 25
11.2%
11.4%
Q2 25
7.2%
23.3%
Q1 25
4.1%
27.4%
Q4 24
20.3%
29.1%
Q3 24
15.2%
35.3%
Q2 24
7.1%
26.1%
Net Margin
DV
DV
LNTH
LNTH
Q1 26
3.5%
Q4 25
14.3%
13.3%
Q3 25
5.4%
7.2%
Q2 25
4.6%
20.8%
Q1 25
1.4%
19.6%
Q4 24
12.3%
-3.0%
Q3 24
10.7%
34.6%
Q2 24
4.8%
15.8%
EPS (diluted)
DV
DV
LNTH
LNTH
Q1 26
$0.04
Q4 25
$0.18
$0.86
Q3 25
$0.06
$0.41
Q2 25
$0.05
$1.12
Q1 25
$0.01
$1.02
Q4 24
$0.14
$-0.18
Q3 24
$0.10
$1.79
Q2 24
$0.04
$0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DV
DV
LNTH
LNTH
Cash + ST InvestmentsLiquidity on hand
$173.8M
$359.1M
Total DebtLower is stronger
$568.7M
Stockholders' EquityBook value
$1.1B
$1.1B
Total Assets
$1.3B
$2.2B
Debt / EquityLower = less leverage
0.52×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DV
DV
LNTH
LNTH
Q1 26
$173.8M
Q4 25
$259.0M
$359.1M
Q3 25
$200.7M
$382.0M
Q2 25
$216.8M
$695.6M
Q1 25
$174.3M
$938.5M
Q4 24
$310.6M
$912.8M
Q3 24
$362.6M
$866.4M
Q2 24
$338.8M
$757.0M
Total Debt
DV
DV
LNTH
LNTH
Q1 26
Q4 25
$568.7M
Q3 25
$567.9M
Q2 25
$566.8M
Q1 25
$566.1M
Q4 24
$565.3M
Q3 24
$613.0K
Q2 24
$563.2M
Stockholders' Equity
DV
DV
LNTH
LNTH
Q1 26
$1.1B
Q4 25
$1.1B
$1.1B
Q3 25
$1.1B
$1.1B
Q2 25
$1.1B
$1.2B
Q1 25
$1.0B
$1.2B
Q4 24
$1.1B
$1.1B
Q3 24
$1.1B
$1.2B
Q2 24
$1.1B
$1.0B
Total Assets
DV
DV
LNTH
LNTH
Q1 26
$1.3B
Q4 25
$1.4B
$2.2B
Q3 25
$1.3B
$2.3B
Q2 25
$1.3B
$2.1B
Q1 25
$1.2B
$2.1B
Q4 24
$1.3B
$2.0B
Q3 24
$1.3B
$2.0B
Q2 24
$1.3B
$1.9B
Debt / Equity
DV
DV
LNTH
LNTH
Q1 26
Q4 25
0.52×
Q3 25
0.51×
Q2 25
0.49×
Q1 25
0.49×
Q4 24
0.52×
Q3 24
0.00×
Q2 24
0.55×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DV
DV
LNTH
LNTH
Operating Cash FlowLast quarter
$4.2M
$90.2M
Free Cash FlowOCF − Capex
$-6.4M
$81.4M
FCF MarginFCF / Revenue
-3.5%
20.0%
Capex IntensityCapex / Revenue
2.2%
Cash ConversionOCF / Net Profit
0.65×
1.67×
TTM Free Cash FlowTrailing 4 quarters
$134.9M
$354.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DV
DV
LNTH
LNTH
Q1 26
$4.2M
Q4 25
$72.7M
$90.2M
Q3 25
$51.2M
$105.3M
Q2 25
$49.6M
$87.1M
Q1 25
$37.7M
$107.6M
Q4 24
$37.4M
$157.7M
Q3 24
$54.6M
$175.1M
Q2 24
$35.9M
$84.7M
Free Cash Flow
DV
DV
LNTH
LNTH
Q1 26
$-6.4M
Q4 25
$62.1M
$81.4M
Q3 25
$39.0M
$94.7M
Q2 25
$40.1M
$79.1M
Q1 25
$31.4M
$98.8M
Q4 24
$30.0M
$141.4M
Q3 24
$48.4M
$159.3M
Q2 24
$28.7M
$73.5M
FCF Margin
DV
DV
LNTH
LNTH
Q1 26
-3.5%
Q4 25
30.2%
20.0%
Q3 25
20.7%
24.7%
Q2 25
21.2%
20.9%
Q1 25
19.0%
26.5%
Q4 24
15.8%
36.1%
Q3 24
28.5%
42.0%
Q2 24
18.4%
18.7%
Capex Intensity
DV
DV
LNTH
LNTH
Q1 26
Q4 25
5.1%
2.2%
Q3 25
6.4%
2.8%
Q2 25
5.0%
2.1%
Q1 25
3.8%
2.3%
Q4 24
3.9%
4.2%
Q3 24
3.7%
4.2%
Q2 24
4.6%
2.8%
Cash Conversion
DV
DV
LNTH
LNTH
Q1 26
0.65×
Q4 25
2.48×
1.67×
Q3 25
5.02×
3.79×
Q2 25
5.66×
1.11×
Q1 25
15.95×
1.47×
Q4 24
1.60×
Q3 24
3.00×
1.34×
Q2 24
4.80×
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DV
DV

Activation$100.5M56%
Measurement$61.8M34%
Supply-side$18.5M10%

LNTH
LNTH

Radiopharmaceutical Oncology$240.2M59%
Definity$85.3M21%
Strategic Partnerships And Other$23.3M6%
Techne Lite$21.0M5%
Licenseand Royalty Revenues$17.4M4%
Other$13.6M3%
Other Precision Diagnostics$5.9M1%

Related Comparisons